238
Views
2
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Molecular Surveillance of Antimicrobial Resistance of Mycobacterium leprae from Leprosy Patients in Zhejiang Province, China

ORCID Icon, , , , , , , & ORCID Icon show all
Pages 4029-4036 | Published online: 27 Jul 2022
 

Abstract

Purpose

Reports on antimicrobial resistance (AMR) of Mycobacterium leprae (M. leprae) in Zhejiang Province are limited. Thus, this study aimed to investigate the drug resistance of new leprosy cases within several years and analyse the emergence of AMR mutations from Zhejiang Province.

Methods

This study enrolled 34 leprosy cases in Zhejiang Province, China, from 2018 to 2021. Gene mutation of WHO-recommended DRDRs (folP1, rpoB and gyrA) and genes of compensatory AMR-associated DRDRs, including nth, rpoA, rpoC, gyrB and 23S rRNA, were detected by amplification. Clinical data analysis was performed to investigate the epidemiological association of leprosy.

Results

Of the 34 samples, 2 (5.9%) strains showed drug resistance, which were mutated to dapsone and ofloxacin, separately. Two single mutations in gyrB were detected in different strains (5.9%), whereas one of the rpoC mutation was also detected in one strain each (2.9%), which were proved to be polymorphs. No correlation of drug resistance proportion was identified in male vs female, nerve vs no nerve involvement, deformity vs no deformity and reaction vs non-reaction cases.

Conclusion

Results showed well control of leprosy patients in Zhejiang Province. Gene mutations of WHO-recommended DRDRs folP1 and gyrA confirmed the resistance to dapsone and ofloxacin. Compensatory AMR-associated mutations confirmed to be polymorphs still require further study to determine their phenotypic outcomes in M. leprae. The results demonstrated that drug-resistant strains are not epidemic in this area. Given the few cases of leprosy, analysing the AMR of M. leprae in Zhejiang Province more comprehensively is difficult. However, regular MDT treatment and population management in the early stage may contribute to the low prevalence of leprosy.

Ethics Approval and Informed Consent

This study was approved by the institutional ethical committee of the Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, China (2014-KY-003) and this study was conducted in accordance with the Declaration of Helsinki. All participants provided written informed consent.

Acknowledgments

We thank all the staff for their support in sample and data collection.

Disclosure

All authors declare that they have no conflicts of interest.

Additional information

Funding

This work was supported by Zhejiang Provincial Natural Science Foundation of China under Grant (LGF19H260001) and National Natural Science Foundation of China (grant 81371751, 81972950).